BioPharmSignal logoBioPharmSignal

Biotech News

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

Prelude Therapeutics (PRLD)Prelude TherapeuticsFDA / regulatory

Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026. WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S.

Related news

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

CGEMCullinan Therapeutics, Inc.2026-10-01 23:30 EST

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

COGTCogent Biosciences2026-09-15 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

KPTIKaryopharm Therapeutics2026-08-31 11:30 EST

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

ELVNEnliven Therapeutics2026-10-06 20:05 EST

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

AUTLAutolus Therapeutics plc2026-09-09 11:00 EST

Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

CMPXCompass Therapeutics2026-09-22 12:30 EST

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

JNJJohnson & Johnson2026-09-21 14:33 EST

European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

RVMDRevolution Medicines2026-09-14 20:05 EST

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

PRLDPrelude Therapeutics2026-09-11 11:01 EST

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

View all latest news

Prelude Therapeutics

Precision Oncology Company Prelude Therapeutics develops medicines for validated cancer targets using selective degradation and mutant-specific inhibition. PRT12396 PRT12396 selectively inhibits mutant JAK2V617F and is in Phase 1 development for polycythemia vera and myelofibrosis. PRT13722 PRT13722 is an oral KAT6A degrader intended for...

Recent company news

PRLDPrelude Therapeutics2026-09-11 11:01 EST

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

PRLDPrelude Therapeutics2026-09-10 11:01 EST

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

PRLDPrelude Therapeutics2026-08-11 11:00 EST

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PRLDPrelude Therapeutics2026-05-12 11:01 EST

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

PRLDPrelude Therapeutics2026-04-20 10:30 EST

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

Stock data

Close
3.81 USD
Market cap
278.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States